Drug intelligence / Profile preview

CM6336

Development stage: Preclinical
Lead developer: CalciMedica
Modality: Small Molecules
Administration: Oral

Overview

CM6336 is an orally bioavailable small molecule inhibitor of calcium-release activated calcium (CRAC) channels, specifically targeting the ORAI1 protein. It is being developed as a chronic oral therapy for inflammatory and autoimmune diseases such as chronic pancreatitis and rheumatoid arthritis. The drug aims to modulate immune responses by inhibiting CRAC channel-mediated calcium entry into cells, thereby reducing inflammation and protecting against tissue injury. CM6336 is currently in preclinical development with investigational new drug (IND) submissions anticipated for both chronic pancreatitis and rheumatoid arthritis. The developer of CM6336 is CalciMedica[1][2][4][5][7].

Targets

ORAI1 (Calcium release–activated calcium channel protein 1)

Beyond the preview

Go deeper on CM6336.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CM6336.

Explore the full profile